Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul Nathan, Jessica C. Hassel, Piotr Rutkowski, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 13, pp. 1196-1206
Open Access | Times Cited: 625

Showing 26-50 of 625 citing articles:

Molecular tumour boards — current and future considerations for precision oncology
Apostolia M. Tsimberidou, Michael Kahle, Henry Hiep Vo, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 12, pp. 843-863
Closed Access | Times Cited: 61
Cancer therapy with antibodies
Suman Paul, Maximilian F. Konig, Drew M. Pardoll, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 6, pp. 399-426
Closed Access | Times Cited: 55
Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review)
Huageng Huang, Yuyi Yao, Xinyi Deng, et al.
International Journal of Oncology (2023) Vol. 63, Iss. 2
Open Access | Times Cited: 47
Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities
Mona Meng Wang, Sarah E. Coupland, Tero Aittokallio, et al.
British Journal of Cancer (2023) Vol. 129, Iss. 8, pp. 1212-1224
Open Access | Times Cited: 46
Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial)
Roger Olofsson Bagge, Axel Nelson, Amir Shafazand, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 16, pp. 3042-3050
Open Access | Times Cited: 45
A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma
Sophie Piperno‐Neumann, Matteo S. Carlino, Valentina Boni, et al.
British Journal of Cancer (2023) Vol. 128, Iss. 6, pp. 1040-1051
Open Access | Times Cited: 43
Bispecific and multispecific antibodies in oncology: opportunities and challenges
Maria-Elisabeth Goebeler, Gernot Stuhler, Ralf C. Bargou
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 539-560
Closed Access | Times Cited: 37
The treatment of advanced melanoma: Current approaches and new challenges
Andrea Boutros, Elena Croce, Marco Ferrari, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 196, pp. 104276-104276
Open Access | Times Cited: 32
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision
Leisha A. Emens, Pedro Romero, Ana C. Anderson, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 6, pp. e009063-e009063
Open Access | Times Cited: 30
A pivotal decade for bispecific antibodies?
Marlena Surowka, Christian Klein
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 20
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
Nanhao Yin, Xintong Li, Xuanwei Zhang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 20
CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes
Sameeha Jilani, Justin D. Saco, Edurne Mugarza, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 17
Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer
Esra Güç, Agatha Treveil, Emma Leach, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
Turning tumors from cold to inflamed to improve immunotherapy response
Camille L. Gérard, Julie Delyon, Alexandre Wicky, et al.
Cancer Treatment Reviews (2021) Vol. 101, pp. 102227-102227
Closed Access | Times Cited: 71
Recent advances and challenges of bispecific antibodies in solid tumors
Yuze Wu, Ming Yi, Shuangli Zhu, et al.
Experimental Hematology and Oncology (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 65
Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma
Richard D. Carvajal, Paul Nathan, Joseph J. Sacco, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 17, pp. 1939-1948
Open Access | Times Cited: 58
Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen
Andrew J. Poole, V. Karuppiah, Annabelle Hartt, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 57
The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies
Mika L. Persson, Alicia M. Douglas, Frank Alvaro, et al.
Neuro-Oncology (2022) Vol. 24, Iss. 9, pp. 1408-1422
Open Access | Times Cited: 48
Emerging Trends in Immunotherapy for Cancer
Alok Mishra, Amjad Ali, Shubham Dutta, et al.
Diseases (2022) Vol. 10, Iss. 3, pp. 60-60
Open Access | Times Cited: 46
Imaging of Uveal Melanoma—Current Standard and Methods in Development
Małgorzata Solnik, Natalia Paduszyńska, Anna M. Czarnecka, et al.
Cancers (2022) Vol. 14, Iss. 13, pp. 3147-3147
Open Access | Times Cited: 44
Recent Advances and Challenges in Uveal Melanoma Immunotherapy
Yihang Fu, Wei Xiao, Yuxiang Mao
Cancers (2022) Vol. 14, Iss. 13, pp. 3094-3094
Open Access | Times Cited: 43
Antibody–drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry
Yeji Hong, Su-Min Nam, Aree Moon
Archives of Pharmacal Research (2023) Vol. 46, Iss. 3, pp. 131-148
Closed Access | Times Cited: 39
Tebentafusp: a first-in-class treatment for metastatic uveal melanoma
Sarah Howlett, Thomas J. Carter, Heather M. Shaw, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 32
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study
William K. Kelly, Daniel C. Danila, Chia‐Chi Lin, et al.
Cancer Discovery (2023) Vol. 14, Iss. 1, pp. 76-89
Open Access | Times Cited: 32
Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer
Emerson A. Lim, Michael T. Schweizer, Kim N., et al.
Clinical Genitourinary Cancer (2023) Vol. 21, Iss. 3, pp. 366-375
Open Access | Times Cited: 29

Scroll to top